cannoli1, thanks for posting those articles. I found the Forbes article particularly interesting, especially the scenario describing the advantages of a takeover after the spinoff. In light of Gerald's comments on the business update call where he made it clear the sale of LymPro is one of the options on the table, it would make sense to let the spinoff entity be acquired vs. selling the asset directly. This approach would generate greater returns for shareholders according to the Forbes article.

I'm kind of surprised your post didn't receive any replies. These articles are definitely worth reading if someone would like to educate themselves more on the spinoff possibilities ahead for Amarantus.